Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia
- PMID: 10400182
- DOI: 10.1016/s0145-2126(98)00194-5
Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia
Abstract
Malignant hematolymphoid disorders arising from natural killer (NK) cells have become widely recognized in the past decade. Recently, we as well as others have drawn attention to some neoplasms of conceivable NK cell precursor origin that might represent two distinct entities, i.e. myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Both of these diseases were characterized by remarkable extramedullary involvement and lymphoblastoid morphology, although the sites of involvement differed. Myeloid/NK cell precursor acute leukemia exhibited more frequent involvement of bone marrow (BM) and lymph nodes, whereas blastic NK cell lymphoma/leukemia affected extranodal sites, mainly the skin/subcutis. Tumor cells of these two diseases shared the CD16-, CD56+ and CD57- phenotype, but differed in other phenotypic profiles. Indeed, myeloid/NK cell precursor acute leukemia was immunophenotypically characterized by the expression of CD34 and blastic NK cell lymphoma/leukemia by that of CD4. On the theoretical level in the NK cell differentiation pathway, myeloid/NK cell precursor acute leukemia might be derived from a myeloid antigen-positive precursor preceding a NK cell committed precursor as a conceivable counterpart of blastic NK cell lymphoma/leukemia. Most cases with either disease lacked cytotoxic activities or molecules, a finding which seems to support their precursor origin. Notably, Epstein Barr virus (EBV) was negative in all cases, which contrasted with its high level associated with mature NK cell malignancies. Chemotherapy for acute myeloid leukemia was generally effective for myeloid/NK cell precursor acute leukemia, while the regimen for lymphoid malignancy was effective for blastic NK cell lymphoma/leukemia. These data suggests that each of these two diseases constitutes a distinct entity, which is also different from mature NK cell malignancies.
Comment in
-
CD56+ hematologic malignancies.Leuk Res. 1999 Jul;23(7):675-6. doi: 10.1016/s0145-2126(99)00074-0. Leuk Res. 1999. PMID: 10400189 No abstract available.
-
Myeloid/natural killer (NK) cell precursor acute leukemia seems not rare among acute myeloid leukemia of M0 subtype (AML-M0).Leuk Res. 2000 Jun;24(6):551. doi: 10.1016/s0145-2126(99)00197-6. Leuk Res. 2000. PMID: 10905910 No abstract available.
Similar articles
-
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity.Blood. 1997 Sep 15;90(6):2417-28. Blood. 1997. PMID: 9310493
-
Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.Br J Haematol. 2001 Apr;113(1):153-60. doi: 10.1046/j.1365-2141.2001.02719.x. Br J Haematol. 2001. PMID: 11328295
-
Uncommon cases of immature-type CD56+ natural killer (NK)-cell neoplasms, characterized by expression of myeloid antigen of blastic NK-cell lymphoma.Int J Hematol. 2009 Mar;89(2):188-194. doi: 10.1007/s12185-008-0233-x. Epub 2008 Dec 25. Int J Hematol. 2009. PMID: 19109730
-
Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.Blood. 1997 Jun 15;89(12):4501-13. Blood. 1997. PMID: 9192774 Review.
-
Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.Leuk Lymphoma. 2000 Jul;38(3-4):317-26. doi: 10.3109/10428190009087022. Leuk Lymphoma. 2000. PMID: 10830738 Review.
Cited by
-
Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas.Curr Treat Options Oncol. 2003 Aug;4(4):289-96. doi: 10.1007/s11864-003-0004-0. Curr Treat Options Oncol. 2003. PMID: 12943609
-
Sjögren's Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature.Case Rep Hematol. 2016;2016:8261249. doi: 10.1155/2016/8261249. Epub 2016 Sep 25. Case Rep Hematol. 2016. PMID: 27882252 Free PMC article.
-
Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate.Int J Hematol. 2010 Nov;92(4):634-7. doi: 10.1007/s12185-010-0660-3. Epub 2010 Oct 9. Int J Hematol. 2010. PMID: 20936384
-
Leukemia and lymphoma of natural killer lineage cells.Int J Hematol. 2003 Jul;78(1):18-23. doi: 10.1007/BF02983235. Int J Hematol. 2003. PMID: 12894846 Review.
-
Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.Int J Hematol. 2024 Jan;119(1):88-92. doi: 10.1007/s12185-023-03678-9. Epub 2023 Nov 27. Int J Hematol. 2024. PMID: 38010569
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous